Unknown

Dataset Information

0

Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target.

ABSTRACT: HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, pertuzumb, lapatinib and ado-trastuzumab emtansine are available. Some patients have shown no response to treatment while others show progress to these agents. Therefore, it is of interest to screen HER2+ with phyto-chemical lead compound from Ginkgo biloba using molecular docking techniques. We screened 25 phyto-chemicals from literature with HER2+. Results show that cianidanol have an acceptable binding energy of (-8.2kcal/mol). Thus, we report the binding properties of cianidanol with HER2+.

SUBMITTER: Arannilewa AJ 

PROVIDER: S-EPMC6563659 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, pertuzumb, lapatinib and ado-trastuzumab emtansine are available. Some patients have shown no response to treatment while others show progress to these agents. Therefore, it is of interest to screen HE  ...[more]

Similar Datasets

Unknown Exploring Substituted Tetrazoloquinazoline: Biological Activities, Molecular Docking Analysis, and Anti-Breast Cancer MCF7/HER2 Effects.
| S-EPMC11374424 | biostudies-literature
Unknown Molecular docking based virtual screening of the breast cancer target NUDT5.
| S-EPMC6936656 | biostudies-literature
Unknown HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
| S-EPMC8201345 | biostudies-literature
Unknown Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine.
| S-EPMC4876844 | biostudies-literature
Unknown Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer.
| S-EPMC9693058 | biostudies-literature
Unknown <i>PIK3CA</i> Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
| S-EPMC8027489 | biostudies-literature
Unknown Structure Based Multitargeted Molecular Docking Analysis of Selected Furanocoumarins against Breast Cancer.
| S-EPMC6823401 | biostudies-literature
Unknown Molecular docking analysis of antimicrobial peptides with the CXCL1 protein target for colorectal cancer.
| S-EPMC8131574 | biostudies-literature
Unknown shRNA kinome screen identifies TBK1 as therapeutic target for HER2+ breast cancer
| S-ECPF-GEOD-53658 | biostudies-other
Unknown GC-MS Analysis, Molecular Docking and Pharmacokinetic Properties of Phytocompounds from Solanum torvum Unripe Fruits and Its Effect on Breast Cancer Target Protein.
| S-EPMC8760204 | biostudies-literature